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Introduction
Advances in the understanding of the complex and hetero-
geneous molecular mechanisms underlying acute myeloid
leukemia (AML) have fuelled a drive towards targeted thera-
py. The development of novel agents targeting individual
molecular lesions, used either alone, in combination, or as an
adjunct to conventional chemotherapy holds considerable
promise for improving clinical responses without increasing
treatment-related toxicity.1
Phosphoinositide-dependent kinase (PDK1) is a serine/thre-
onine protein kinase that phosphorylates and activates at
least six kinase groups in the AGC superfamily.2,3 Many of
these kinases have been shown to be constitutively active in
tumor tissue including: AKT,4 S6K,5 SGK,6 RSK7 and PKC iso-
forms.8 Genetic knockout studies have demonstrated that
PDK1 is essential for the activation of these kinases.9,10 PDK1
is a constitutively active kinase11 with substrate phosphoryla-
tion being largely regulated by co-localization or substrate
conformation.12 In the case of AKT, phosphorylation by PDK1
is dependent on phosphatidylinositol (3,4,5)-trisphosphate
(PIP3) production that binds the pleckstrin homology domains
of PDK1 and AKT and co-localizes these kinases at the plas-
ma membrane. In contrast, phosphorylation of S6K, SGK and
RSK by PDK1 is dependent on a conformational change in
these kinases induced by cell stimulation. PKC isoforms are
thought to be constitutively phosphorylated by PDK1 during
synthesis and are vital for maintaining the stability of conven-
tional and novel PKC isoforms.10,13
The ability of PDK1 to activate multiple substrates may
explain the influence of this kinase on a variety of cellular
processes including proliferation,14 migration15 and survival.16
Constitutive knockout of PDK1 gives rise to embryonic
lethality, but in contrast, hypomorphic mice (which express
approx. 10% of the normal levels of PDK1) are viable and fer-
tile suggesting that normal cells are able to compensate for
low levels of PDK1 activity.17 These mice are also resistant to
hematologic malignancy as well as other cancers when
crossed with the highly cancer-prone PTEN-deficient mice.18
PDK1(–/–) ES cells also have low tumorigenic potential com-
pared to PDK1(+/+)cells.19 Consistent with these observations,
PDK1 overexpression is a common feature of a wide variety
of cancers20-23 and an RNAi screen has identified PDK1 as
being the most important factor in mediating resistance to
tamoxifen in breast cancer.24 An essential role for PDK1 has
also recently been identified in pancreatic cancer.25 These
data, together with its role as a master kinase regulator, have
established PDK1 as a significant drug target in cancer, and it
is also one of the few kinases represented in higher eukaryot-
ic genomes as a single isoform increasing its tractability as a
drug target. Further, since 50% of all cancers including
leukemias possess mutations in genes that dysregulate PIP3
production,4,26 overstimulation of PDK1 signaling may be
extremely common. At the same time, the fact that normal
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PDK1 is a master kinase that activates at least six protein kinase groups including AKT, PKC and S6K and is a
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range) suggesting oncogene addiction, whilst normal bone marrow progenitors were refractory to PDK1 inhibition
at effective inhibitor concentrations. PDK1 inhibition also targeted subpopulations of leukemic blasts with a puta-
tive leukemia-initiating cell phenotype. Together these data show that overexpression of PDK1 is common in
acute myelomonocytic leukemia and is associated with poorer treatment outcome, probably arising from the cyto-
protective function of PDK1. We also show that therapeutic targeting of PDK1 has the potential to be both an
effective and selective treatment for these patients, and is also compatible with current treatment regimes.
The PDK1 master kinase is over-expressed in acute myeloid leukemia
and promotes PKC-mediated survival of leukemic blasts
Joanna Zabkiewicz, Lorna Pearn, Robert K. Hills, Rhys G. Morgan, Alex Tonks, Alan K. Burnett, and Richard L. Darley
Department of Haematology, Institute of Cancer and Genetics, School of Medicine, Cardiff University, UK
ABSTRACT
cells tolerate very low levels of PDK1 activity (similar to
that which would be achieved through the use of a pow-
erful PDK1 inhibitor18,26) suggests that PDK1 inhibition
should be selectively toxic for cancer cells. 
Previously we identified PDK1 overexpression in
myelomonocytic AML (FAB M4 and M5).27 Here we show
that PDK1 overexpression is associated with poor clinical
outcome, and that while overexpression promotes the sur-
vival of AML blasts, they are highly sensitive to PDK1
inhibition.  
Methods
Cell culture and patients’ samples
AML patient material (Online Supplementary Table S1) and nor-
mal bone marrow were collected with approval from the Research
Ethics Committee for South East Wales and the Multi-Centre
Research Ethics Committee for Wales in accordance with the
Declaration of Helsinki. Mononuclear cells from AML patients
were purified by Ficoll density gradient and analyzed for blast con-
tent by flow cytometry following staining with CD45. Samples
with more than 70% blasts following density gradient fractiona-
tion were employed in subsequent analysis. AML blasts were cul-
tured in IMDM (Sigma, Poole, UK) with 10% FCS (Biosera,
Ringmer, UK).  Normal bone marrow CD34+ cells were isolated
using MiniMACS (Miltenyi Biotec, Bisley, UK) according to the
manufacturer’s instructions. Cell lines were cultured as recom-
mended by ATCC-LGC (http://www.lgcstandards-atcc.org). All cul-
tures were incubated at 37°C, 5% CO2.  Cell viability was deter-
mined by Trypan blue exclusion using a Vicell-XR viability analyz-
er (Beckman Coulter, Fullerton, CA, USA). PDK1 was subcloned
into bicistronic PINCO vector and retrovirus generated as previ-
ously described.27 Transduction efficiency of 40-50% was moni-
tored through co-expression of GFP and positive cells selected
using FACSAria cell sorter (BD Biosciences, Oxford, UK).
Western blot analysis
Sample preparation of fractionated and non-fractionated lysates
and Western blotting was performed as previously described.27,28
Further details are provided in the Online Supplementary Methods. 
Flow cytometric analysis of cell survival and 
intracellular PDK1 staining
Cell survival/drug response assays were set up in 96 U-well
plates with 5x104 AML cells per well.  Some experiments
employed the PDK1 inhibitor, BX-795 (MRC Protein
Phosphorylation Unit, University of Dundee, UK).  For cytosine
arabinoside (AraC) synergy experiments, dose response assays
were set up for singly- and combination-treated AML cells using
clinically relevant AraC doses.  Cells were harvested after 48 h and
resuspended in 1 mg/mL 7-amino-actinomycin D (7AAD) to deter-
mine viable cells remaining. In some experiments, samples were
pre-stained with surface markers: CD34-FITC, CD123-PE and
CD45-APC or isotype control (BD Biosciences, Oxford, UK), prior
to harvesting and analysis on a FACSCalibur® cytometer (BD).
EC50 and combination index values were determined using
Calcusyn v.2.0 software (Biosoft, Cambridge, UK). For PKC
inhibitor analysis, cells were treated with Chelerythrine (CC) and
Bisindolylmaleimide (BIM1) (both LC laboratories) under reduced
serum conditions and cell proliferation was measured by
CellTiter96® MTS reagent (Promega).
For intracellular PDK1 staining, AML blasts were pre-stained for
30 min at 4°C with surface markers as above then fixed in fresh
2% paraformaldehyde for 20 min and permeabilized in PBS 0.1%
Triton for 5 min before incubation with 1 mg/mL rabbit anti-PDK1
(1624-1; Epitomics, Burlingame, CA, USA) or rabbit IgG control
for 30 min at 20°C. Finally, cells were labeled with goat-anti-rabbit
PE-conjugated secondary antibody (L43004, Caltag Laboratories,
Bucks, UK) for 30 min at 20°C.
Statistical analysis
Multivariable analyses were performed using either logistical or
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Figure 1. PDK1 overexpression confers
poor clinical outcome in M4/M5
patients and is represented throughout
the leukemic clone. (A) PDK1 protein
expression in 66 myelomonocytic AML
patients (data are expressed as fold
change relative to normal bone marrow
CD34+ cells; n=5). The threshold of
overexpression (mean+2SD) is indicat-
ed by the dotted line. (B) Kaplan-Meier
plot for intensively treated patients sig-
nificantly over-expressing PDK1
(PDK1Hi) compared with those express-
ing statistically normal levels (PDK1Norm)
in M4/M5 AML (n=66). Hazard ratio
95% CI (0.98-4.21) P=0.05 adjusted for
known prognostic variables.  No signifi-
cant difference in complete remission
was observed. (C) Representative cyto-
metric data demonstrating homoge-
neous intracellular PDK1 expression in
leukemic (CD123+ ) subpopulations. (D)
Bar chart summarizing PDK1 expres-
sion in CD34+ compared with CD34neg
leukemic populations (n=8).  
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Cox proportional hazard regression methods adjusted for age,
white blood cell count, cytogenetic group, performance status, de
novo/secondary disease and gender. Hazard ratios (HR) quoted for
95% confidence intervals.  P values are two-tailed. For all other
results, differences between mean values were compared by
Minitab v.13 (Minitab Inc.; PA, USA) using Mann Whitney-U or
paired t-test.
Results
PDK1 overexpression is associated with poor clinical
outcome and occurs throughout the leukemic clone  
To investigate the clinical significance of PDK1 overex-
pression in myelomonocytic AML patients, we analyzed
PDK1 protein expression in a cohort of 66 patients (Online
Supplementary Table S1) by Western blot analysis. We
observed up to 5-fold overexpression in 42% of these
patients (Figure 1A). Analysis of the association between
PDK1 expression level, patients’ characteristics and clinical
outcome showed that overexpression was associated with
poorer overall survival (Figure 1B).
AML is a clonally heterogeneous disease29 where some
abnormalities (such as FLT3) may occur only in a subpop-
ulation of leukemic blasts; in addition there is functional
heterogeneity defined by xenograft models where
leukemia-initiating cells (LIC) are often (though not exclu-
sively) associated with CD34 expression.30 In order to
determine whether PDK1 was over-expressed throughout
the malignant clone, we determined PDK1 expression at a
single cell level using flow cytometry. Intracellular staining
of PDK1 was validated using KG-1 cells retrovirally trans-
duced to over-express PDK1 (Online Supplementary Figure
S1). We applied this method to analyze the expression of
PDK1 in AML blasts that were surface-labeled with CD34,
CD45 and the leukemic blast cell marker, CD123.31 We
analyzed 8 AML patients and in all cases found PDK1 to
be uniformly expressed throughout the malignant clone
(Figure 1C). Comparison of expression in CD34neg, CD123+
cells with the CD34+, CD123+ subset of blasts showed
that PDK1 was expressed at similar levels in both popula-
tions in all patients tested (Figure 1C and D). These data
show that PDK1 overexpression is an inherent property of
the entire leukemic blast population including elements
most closely associated with the LIC population.
Together these data indicate that PDK1 overexpression
is a common abnormality in myelomonocytic AML,
occurs throughout the leukemic clone, and negatively
impacts on the survival of AML these patients.
PDK1 overexpression promotes cell survival in
myelomonocytic AML 
Since PDK1 targets a number of AGC kinases that are
associated with promoting cell survival,3 we examined
whether PDK1 overexpression promoted the survival of
myelomonocytic AML blasts. To address this, we com-
pared the in vitro survival of over-expressing (PDK1Hi)
blasts compared with the PDK1Norm control group in
growth factor-free cultures for 48 h by Trypan blue exclu-
sion. Those patients with high PDK1 expression displayed
significantly better survival (82%±13.3 in PDK1Hi vs.
57%±14.9 in PDK1Norm; P<0.001) (Figure 2A).  Even when
assayed in the presence of growth factors (IL3, G-CSF,
GM-CSF, SCF), PDK1Hi cells still retained a survival advan-
tage (Online Supplementary Figure S2). These data suggest
that overexpression of PDK1 promotes the survival of
AML blasts.  
To establish whether this association was causally relat-
ed, we over-expressed PDK1 in the monocytic cell line,
THP1. We found that THP1 cells ectopically expressing
PDK1 displayed a 61% increase in survival compared to
controls using 7AAD exclusion under reduced serum con-
ditions (Figure 2B). Similarly, overexpression of PDK1 in
normal CD34+ cells also resulted in significantly improved
cell survival (Figure 2C).
Together these data indicate that overexpression of PDK1
promotes the survival of myelomonocytic AML blasts.
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Figure 2.  PDK1 overexpression promotes in vitro cell survival in AML
blasts. (A) Viability of PDK1Hi AML blasts (n=28) compared with
PDK1Norm AML blasts (n=29) scored by trypan blue at 48 h in
cytokine-free medium (**P<0.001). (B) Viability of THP1 cells over-
expressing PDK1 (THP1PDK1) compared with vector control cells
(THP1Cntl) by 7AAD exclusion after 48 h of reduced serum culture;
*P<0.05, **P<0.001. Top panel shows PDK1 expression in each line
by Western blot. (C) Equivalent analysis of the effect of PDK1 over-
expression (indicated by Western blot) on the survival of normal
CD34+ cells (0.5% FCS; n=4;*P<0.05 paired t-test). 
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PDK1 promotes survival through PKC activation 
To establish which of the downstream targets of PDK1
was responsible for mediating the pro-survival effect of
PDK1, we carried out a survey of PDK1 target kinases
including AKT, SGK, S6K, PKC, RSK and PAK. Of these
RSK, PAK and S6K phosphorylation was not detected
(data not shown) though we were able to detect phospho-
rylation of the S6K substrate, S6. In a sample of 20
myelomonocytic patients, no association between PDK1
overexpression and the phosphorylation of AKT, SGK1/2
or S6 was observed (Figure 3A); however, we did find that
the level of PDK1 expression correlated directly with the
phosphorylation of conventional and novel isoforms of
PKC (Figure 3A and B).  
These data imply that PDK1 expression is a limiting fac-
tor in PKC phosphorylation in this context and that the
survival of AML blasts in vitro is related to their level of
PKC phosphorylation. In support of this, we observed a
close correlation between PKC phosphorylation and the 
in vitro survival of AML blasts (Figure 3C). Furthermore,
inhibition of PKC using 2 different pan-isoform PKC
inhibitors: Chelerythrine chloride (CC, peptide site com-
petitive PKC inhibitor) and Bisindolylmaleimide 1 (BIM1,
adenosine triphosphate site competitive PKC inhibitor)
was able to abrogate the pro-survival effect of PDK1 over-
expression in THP1 cells (Figure 3D and Online
Supplementary Figure S3A-C). Since phospho-specific anti-
bodies are not available for each PKC isoform, and mem-
brane localization is key to activity, we analyzed PKC iso-
form activation by assessing their membrane localization
in plasma membrane fractions derived from AML
patients. This analysis showed a direct correlation
between PDK1 expression and the membrane transloca-
tion of PKCα (Figure 3E and F).  
Overall these data suggest that PDK1 promotes PKC
activity in the context of myelomonocytic AML and that
this contributes to their increased in vitro survival.
AML blasts are selectively sensitive to PDK1 inhibition
The above data suggested that targeting PDK1 could be
effective in the treatment of myelomonocytic AML
patients. To determine whether AML blasts over-express-
ing PDK1 were selectively sensitive to PDK1 inhibition,
we assessed the efficacy of BX-795,32 a pyrimidine deriva-
tive with high potency for PDK1 in vitro (IC50 10-30nM)
using flow cytometry. We found that BX-795 was effec-
tive against PDK1Hi AML blasts, but showed little toxicity
against normal bone marrow CD34+ blasts (Figure 4A). In
addition, PDK1Hi AML blasts displayed twice the sensitiv-
ity to PDK1 inhibition compared to PDK1Norm blasts
PDK1 overexpression in AML
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Figure 3. PDK1 expression corre-
lates with PKC phosphorylation and
pro-survival function in myelomono-
cytic AML. (A) Representative data
(from 6 of 20 patients assayed)
illustrating PDK1 target kinase
phosphorylation in PDK1Norm and
PDK1Hi patients. (B) Correlation of
PDK1 and pPKC protein levels
(n=20 patients). (C) pPKC levels in
relation to cell viability at 24 h and 
48 h (n=8 patients).  pPKC units
represent fold change relative to
expression level in normal bone
marrow (NBM) CD34+ cells (n=5).
(D) Cell survival assay under serum
deprived conditions (measured by
MTS) of THP1PDK1 and THP1cntl
cells in the presence of
Chelerythrine (CC, 0.3 mM) and
Bisindolylmaleimide 1 (BIM1, 
7.5 mM). (E) Representative Western
blot of effect of PDK1 expression on
the membrane localization of PKCα
in primary AML samples (C: cyto-
plasmic; M: membrane).  CD45
staining demonstrates purity of the
membrane fractions 
(F) Summary data of the relation-
ship between PDK1 expression and
level of membrane-associated
PKCα measured by Western blot of
fractionated primary AML samples
(n=15).  Units represent fold change
relative to expression levels in nor-
mal bone marrow (NBM) CD34+
cells (n=5).
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(PDK1Hi 6.4 mM±2.8 vs. PDK1Norm 13.6 mM±7.3) (Figure
4B). As predicted from previous studies19,32 BX-795 was
able to inhibit the phosphorylation of PKC and S6 in these
patients (Figure 4C). Inhibition of AKT phosphorylation
was also observed, but only at high dose.  
To establish whether PDK1 inhibition could also effec-
tively target leukemic sub-populations, we examined
whether CD34+/CD123+ leukemic cells were also sensitive
to PDK1 inhibition. Across all patients surveyed, we found
that CD34+/CD123+ leukemic cells were equally or more
sensitive to BX-795 compared with CD34neg leukemic sub-
populations (Figure 4D) suggesting that all subpopulations
are sensitive to PDK1 inhibition.  
Since the use of new agents in AML is normally com-
bined with cytarabine (AraC), we examined the effective-
ness of AraC and BX-795 when used in combination. We
found moderate synergy between the two agents in cell
lines and in most primary AML (Online Supplementary
Figure S4).  
Overall these data show that PDK1 inhibition is effec-
tive in AML, particularly where PDK1 is over-expressed
and that PDK1 inhibitors could be used to augment the
activity of existing regimens.
Discussion 
PDK1 is a constitutively active kinase12,13 and no gain of
function mutations have yet been identified in human
cancer. In this context, therefore, it is unsurprising that
overexpression of PDK1 is frequently observed in a variety
of human cancers.20-23 We show here that PDK1 overex-
pression is frequently observed in myelomonocytic AML
and that expression is uniformly expressed throughout the
AML blast population (including putative LIC) implicating
PDK1 overexpression in the pathogenesis of AML. In sup-
port of this, overexpression of PDK1 has been implicated
in the development of prostate and pancreatic cancer in
vivo25,33-35 and has been shown to transform mouse mam-
mary epithelial cells in vitro.36 The mechanism of overex-
pression is unclear; it has been reported that Meis3 up-reg-
ulated PDK1 transcription;37 however, in our microarray
database of 205 AML patients we found no correlation
between Meis3 and PDK1 mRNA expression which also
correlated poorly with PDK1 protein levels (data not
shown). This observation is in accord with our previous
data that suggested that PDK1 overexpression in this con-
text arises from a post-translation mechanism.27 In terms
of treatment outcome, our data show that overexpression
of PDK1 in myelomonocytic AML was associated with
poor treatment outcome which could be linked with the
cytoprotective effect of PDK1 overexpression that we
observed both in primary AML blasts and cell lines. This
compliments several other studies where PDK1 is known
to have a pro-survival role in cancer cells.23,35,38 Although
AKT is a substrate for PDK1, and is commonly associated
with pro-survival signaling, we were unable to demon-
strate a correlation between PDK1 expression and the
phosphorylation of AKT, possibly because this phospho-
rylation is also dependent on the level of PIP3. Data
employing a new highly selective PDK1 inhibitor
(GSK2334470) suggest that only very low levels of active
PDK1 are required to efficiently phosphorylate AKT;39
hence AKT phosphorylation is not limited by PDK1
expression level and it is, therefore, unlikely that PDK1
overexpression is driven by the need to promote phospho-
rylation of AKT. In support of this, PTEN tumor suppres-
sor or PIK3CA oncogene mutations strongly drive PDK1
activation but are associated with only minimal activation
of AKT.38 Of all the PDK1 substrates whose phosphoryla-
tion was detectable in AML blasts, we observed that only
the phosphorylation of PKC isoenzymes was directly
J. Zabkiewicz et al.
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Figure 4.  BX-795 induces cell death
in AML blasts over-expressing PDK1.  
(A) Effect of BX-795 on the survival of
normal bone marrow (NBM) CD34+
blasts (n=6) and representative
PDK1Hi primary AML blasts.  Survival
is expressed as percentage viability
compared with cells treated with
vehicle alone. (B) Half maximal effec-
tive concentration (EC50) of BX-795
between PDK1Hi (n=26) and PDK1Norm
(n=32) M4/M5 AML blasts 
(**P<0.001).  (C) Western blot analy-
sis of PDK1 target kinase phosphory-
lation following 60 min incubation
with BX-795; data representative of 9
patient samples analyzed.  (D) BX-
795 EC50 levels in the total AML
blast population compared with the
CD34+, CD123+ subpopulation.  
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related to PDK1 expression level. Further investigation
showed PDK1 expression to be closely associated with
increased activation of PKCα. Overexpression of PDK1 in
mammary epithelial cells similarly promotes transforma-
tion through activation and stabilization of PKCα but not
AKT.40 PKCα has also been linked to poor survival in
AML41 and has been associated with blocking apoptosis
in myelomonocytic patients,42 suggesting hyperactivation
of this pathway is advantageous in promoting treatment
resistance in these patients. These reports, together with
our own data, strongly implicate PKCα in the in vitro sur-
vival advantage of AML blasts over-expressing PDK1,
although it is possible that PDK1 overexpression may also
contribute to the activation of other targets, such as AKT,
that may provide cooperative pro-survival function. 
In contrast to normal blasts, we found that PDK1Hi AML
blasts were highly sensitive to PDK1 inhibition.
Furthermore, PDK1Hi blasts also showed greater sensitivity
to inhibition than corresponding PDK1Norm blasts, suggest-
ing that overexpression marked a stronger dependency on
PDK1 to maintain their viability. PDK1 overexpression
may, therefore, be an example of ‘oncogene addiction’
(where cancer cells become dependent on one or several
genes for maintenance of cell survival).43 Other PDK1 tar-
geting agents have shown selectivity for AML versus nor-
mal blasts44 and BX compounds have also been shown to
selectively promote the apoptosis of breast cancer cells
compared with normal epithelial cells.32 Our data also
showed that phenotypic leukemic subpopulations (CD34+
CD123+) present in myelomonocytic AML were equally
sensitive to PDK1 inhibition compared with the bulk
leukemic population, indicating that this agent also has
the potential to target subpopulations associated with
LIC,31 although further in vivo engraftment experiments
would be required to prove this.  
Targeting PDK1 holds the promise of inhibiting a variety
of signaling pathways associated with leukemogenesis
while retaining specificity for a single gene product that is
functionally non-redundant. This situation contrasts with
some of the complexities that have arisen from attempting
to target PKC directly.45 Our data also show that PDK1
inhibition decreased the phosphorylation of all detectable
PDK1 targets and it is likely that this combined effect con-
tributed to the efficacy of BX-795. 
In summary, we have identified PDK1 targeting in
myelomonocytic AML as a novel therapeutic strategy with
the potential for good therapeutic index, targeting the entire
leukemic clone (including putative LIC), and it is predicted
to be a safe and effective adjunct to conventional treatment.
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